Analysts See $-0.25 EPS for CTI BioPharma Corp. (CTIC)

July 11, 2018 - By Mona Holcomb

CTI BioPharma Corp. (NASDAQ:CTIC) Logo

Analysts expect CTI BioPharma Corp. (NASDAQ:CTIC) to report $-0.25 EPS on August, 2.They anticipate $0.28 EPS change or 933.33 % from last quarter’s $0.03 EPS. After having $-0.08 EPS previously, CTI BioPharma Corp.’s analysts see 212.50 % EPS growth. The stock decreased 2.79% or $0.13 during the last trading session, reaching $4.53. About 326,791 shares traded. CTI BioPharma Corp. (NASDAQ:CTIC) has risen 15.83% since July 12, 2017 and is uptrending. It has outperformed by 3.26% the S&P500.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Coverage

Among 3 analysts covering CTI BioPharma (NASDAQ:CTIC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CTI BioPharma had 3 analyst reports since February 23, 2018 according to SRatingsIntel. On Monday, March 26 the stock rating was initiated by Needham with “Buy”.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company has market cap of $262.65 million. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. It currently has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.

More notable recent CTI BioPharma Corp. (NASDAQ:CTIC) news were published by: which released: “Mid-Morning Market Update: Markets Open Higher; Helen of Troy Beats Q1 Expectations” on July 09, 2018, also with their article: “CTI BioPharma (CTIC) Announces Continuation without Modification of PAC203 Phase 2 Study of Pacritinib Following …” published on July 02, 2018, published: “The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus” on June 30, 2018. More interesting news about CTI BioPharma Corp. (NASDAQ:CTIC) were released by: and their article: “Pre-Open Movers 07/10: (OCX) (VVUS) (XLRN) Higher; (ISR) (AQXP) (IRBT) Lower (more…)” published on July 10, 2018 as well as‘s news article titled: “CTI Bio’s Pixuvri flunks late-stage NHL study; shares halted” with publication date: July 09, 2018.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: